Question-and-Answer Session
Operator
Thank you, sir. We will now begin the question-and-answer session. (Operator Instructions) Our first question comes from the line of Gerard Holt with Thomas Weisel Partners, please go ahead.
Gerard Holt – Thomas Weisel Partners
I guess to somewhat argue that, over the last given all the compliance issues of the larger orthopedic companies, that this has been maybe the largest window of opportunity for small companies to gain market share in orthopedics, but it actually looks like Exactech might be losing share here. So can you just help reconcile that, just give us a sense of what we can expect, maybe in 2010 when things turn around?
William Petty
This is Bill speaking. I’m a little puzzled by your first premise as to why that would be. Certainly, we would like to see a future where all companies are playing by the same rules and I think all companies want to do that and all companies want to follow the law, but I don’t personally understand the premise of the window of opportunities.
Your second question, I think from the standpoint of me, and I have looked at some of the competitors reports, and I could see why one would interpret that as the loss in market share and I’ll ask David Petty to address that a little bit more. I think, pretty much in all of our other competitive product segments, certainly if and extremity would suggest that Exactech is gaining market share in those areas with a growth of 18%, 29%, I haven’t seen anyone else report those kind of numbers.
David do you have further comments about that?
David Petty
Yes. I’ll go back all into the spirit of the question, which is you asked about 2010 and we’re not going to be specifically predictive about growth rates for the future and we never do.
I think the reality here is what drives the growth and customer acquisition, is really is having good technology that improves our consultation. That’s something that the tenant for Exactech as always has been.
When we think about the launch of our CR Slope Knee and the eminent launch of our posterior stabilized PS Logic version of the Optetrak Knee, both of which has been very well received, and in combination with the local file instruments or instruments presentably invasive, approaches of the knees for tibia and the patella. I think those are the things that are the real drivers of what should make us feel good about our future and acquiring customers with the knee.
- To read the full transcript on Seeking Alpha, click here »
